VPIM
HRTX icon

Vanguard Personalized Indexing Management’s Heron Therapeutics HRTX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7K Sell
13,428
-1,468
-10% -$1.7K ﹤0.01% 2152
2025
Q4 		$19.4K Buy
14,896
+75
+0.5% +$93 ﹤0.01% 1941
2025
Q3 		$18.7K Sell
14,821
-898
-6% -$1.42K ﹤0.01% 1966
2025
Q2 		$32.5K Sell
15,719
-40
-0.3% -$82 ﹤0.01% 1867
2025
Q1 		$34.7K Sell
15,759
-18
-0.1% -$35 ﹤0.01% 1713
2024
Q4 		$24.1K Buy
15,777
+2,639
+20% +$4.28K ﹤0.01% 1755
2024
Q3 		$26.1K Sell
13,138
-136
-1% -$325 ﹤0.01% 1726
2024
Q2 		$46.5K Buy
13,274
+136
+1% +$418 ﹤0.01% 1593
2024
Q1 		$36.4K Hold
13,138
– – ﹤0.01% 1582
2023
Q4 		$22.3K Buy
+13,138
New +$14.5K ﹤0.01% 1545

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Vanguard Personalized Indexing Management's HRTX Position: Q1 2026 in Review

Vanguard Personalized Indexing Management reduced its Heron Therapeutics (HRTX) stake by 9.9% in Q1 2026, selling an estimated $1.7K and leaving 13,428 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2152.

Vanguard Personalized Indexing Management first reported a position in HRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $46.5K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Vanguard Personalized Indexing Management held 13,428 shares of Heron Therapeutics worth $10.7K as of Q1 2026.
  • Vanguard Personalized Indexing Management sold 1,468 Heron Therapeutics shares in Q1 2026, an estimated $1.7K.
  • Heron Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #2152 holding.
  • Vanguard Personalized Indexing Management first reported a position in Heron Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Vanguard Personalized Indexing Management's Heron Therapeutics position peaked at $46.5K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.